Incidence of Microemboli and Correlation with Platelet Inhibition in Aneurysmal Flow Diversion

REFERENCES

1. 1.↵
   1. Nelson PK,
   2. Lylyk P,
   3. Szikora I,
   4. et al

   . The Pipeline embolization device for the intracranial treatment of aneurysms trial. AJNR Am J Neuroradiol 2011;32:34–40

   Abstract/FREE Full Text
2. 2.↵
   1. Briganti F,
   2. Napoli M,
   3. Tortora F,
   4. et al

   . Italian multicenter experience with flow-diverter devices for intracranial unruptured aneurysm treatment with periprocedural complications—a retrospective data analysis. Neuroradiology 2012;54:1145–52

   CrossRefPubMedWeb of Science
3. 3.↵
   1. Cruz JP,
   2. Chow M,
   3. O'Kelly C,
   4. et al

   . Delayed ipsilateral parenchymal hemorrhage following flow diversion for the treatment of anterior circulation aneurysms. AJNR Am J Neuroradiol 2012;33:603–08

   Abstract/FREE Full Text
4. 4.↵
   1. Velat GJ,
   2. Fargen KM,
   3. Lawson MF,
   4. et al

   . Delayed intraparenchymal hemorrhage following Pipeline embolization device treatment for a giant recanalized ophthalmic aneurysm. J Neurointerv Surg 2012;4:e24

   Abstract/FREE Full Text
5. 5.↵
   1. Fischer S,
   2. Vajda Z,
   3. Aguilar Perez M,
   4. et al

   . Pipeline embolization device (PED) for neurovascular reconstruction: initial experience in the treatment of 101 intracranial aneurysms and dissections. Neuroradiology 2012;54:369–82

   CrossRefPubMedWeb of Science
6. 6.↵
   1. Deshmukh V,
   2. Hu YC,
   3. McDougall CG,
   4. et al

   . Histopathological assessment of delayed ipsilateral parenchymal hemorrhages after the treatment of paraclinoid aneurysms with the Pipeline embolization device. In: Proceedings of the Congress of Neurological Surgeons 2012 Annual Meeting, Chicago, Illinois. October 6–10, 2012
7. 7.↵
   1. King A,
   2. Markus HS

   . Doppler embolic signals in cerebrovascular disease and prediction of stroke risk: a systematic review and meta-analysis. Stroke 2009;40:3711–17

   Abstract/FREE Full Text
8. 8.↵
   1. Schubert GA,
   2. Thome C,
   3. Seiz M,
   4. et al

   . Microembolic signal monitoring after coiling of unruptured cerebral aneurysms: an observational analysis of 123 cases. AJNR Am J Neuroradiol 2011;32:1386–91

   Abstract/FREE Full Text
9. 9.↵
   1. Klötzsch C,
   2. Nahser HC,
   3. Henkes H,
   4. et al

   . Detection of microemboli distal to cerebral aneurysms before and after therapeutic embolization. AJNR Am J Neuroradiol 1998;19:1315–18

   Abstract
10. 10.↵
    1. Müller-Schunk S,
    2. Linn J,
    3. Peters N,
    4. et al

    . Monitoring of clopidogrel-related platelet inhibition: correlation of nonresponse with clinical outcome in supra-aortic stenting. AJNR Am J Neuroradiol 2008;29:786–91

    Abstract/FREE Full Text
11. 11.↵
    1. Lee DH,
    2. Arat A,
    3. Morsi H,
    4. et al

    . Dual antiplatelet therapy monitoring for neurointerventional procedures using a point-of-care platelet function test: a single-center experience. AJNR Am J Neuroradiol 2008;29:1389–94

    Abstract/FREE Full Text
12. 12.↵
    1. Prabhakaran S,
    2. Wells KR,
    3. Lee VH,
    4. et al

    . Prevalence and risk factors for aspirin and clopidogrel resistance in cerebrovascular stenting. AJNR Am J Neuroradiol 2008;29:281–85

    Abstract/FREE Full Text
13. 13.↵
    1. Pandya DJ,
    2. Fitzsimmons BF,
    3. Wolfe TJ,
    4. et al

    . Measurement of antiplatelet inhibition during neurointerventional procedures: the effect of antithrombotic duration and loading dose. J Neuroimaging 2010;20:64–69

    CrossRefPubMedWeb of Science
14. 14.↵
    1. Reavey-Cantwell JF,
    2. Fox WC,
    3. Reichwage BD,
    4. et al

    . Factors associated with aspirin resistance in patients premedicated with aspirin and clopidogrel for endovascular neurosurgery. Neurosurgery 2009;64:890–95, discussion 895–96

    CrossRefPubMed
15. 15.↵
    1. Ono T,
    2. Kaikita K,
    3. Hokimoto S,
    4. et al

    . Determination of cut-off levels for on-clopidogrel platelet aggregation based on functional CYP2C19 gene variants in patients undergoing elective percutaneous coronary intervention. Thromb Res 2011;128:e130–136

    CrossRefPubMed
16. 16.↵
    1. Godino C,
    2. Mendolicchio L,
    3. Figini F,
    4. et al

    . Comparison of VerifyNow-P2Y12 test and Flow Cytometry for monitoring individual platelet response to clopidogrel: what is the cut-off value for identifying patients who are low responders to clopidogrel therapy? Thromb J 2009;7:4

    CrossRefPubMed
17. 17.↵
    1. Mega JL,
    2. Hochholzer W,
    3. Frelinger AL,
    4. et al

    . Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. JAMA 2011;306:2221–28

    CrossRefPubMedWeb of Science
18. 18.↵
    1. Cuisset T,
    2. Quilici J,
    3. Cohen W,
    4. et al

    . Usefulness of high clopidogrel maintenance dose according to CYP2C19 genotypes in clopidogrel low responders undergoing coronary stenting for non ST elevation acute coronary syndrome. Am J Cardiol 2011;108:760–65

    CrossRefPubMed
19. 19.↵
    1. Malinin A,
    2. Pokov A,
    3. Spergling M,
    4. et al

    . Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study. Thromb Res 2007;119:277–84

    CrossRefPubMedWeb of Science
20. 20.↵
    1. McAuliffe W,
    2. Wycoco V,
    3. Rice H,
    4. et al

    . Immediate and midterm results following treatment of unruptured intracranial aneurysms with the Pipeline embolization device. AJNR Am J Neuroradiol 2012;33:164–70

    Abstract/FREE Full Text
21. 21.↵
    1. Mocco J,
    2. Snyder KV,
    3. Albuquerque FC,
    4. et al

    . Treatment of intracranial aneurysms with the Enterprise stent: a multicenter registry. J Neurosurg 2009;110:35–39

    CrossRefPubMedWeb of Science
22. 22.↵
    1. Piotin M,
    2. Blanc R,
    3. Spelle L,
    4. et al

    . Stent-assisted coiling of intracranial aneurysms: clinical and angiographic results in 216 consecutive aneurysms. Stroke 2010;41:110–15

    Abstract/FREE Full Text
23. 23.↵
    1. Fargen KM,
    2. Hoh BL,
    3. Welch BG,
    4. et al

    . Long-term results of Enterprise stent-assisted coiling of cerebral aneurysms. Neurosurgery 2012;71:239–44, discussion 244

    CrossRefPubMed
24. 24.↵
    1. Rordorf G,
    2. Bellon RJ,
    3. Budzik RE Jr.,
    4. et al

    . Silent thromboembolic events associated with the treatment of unruptured cerebral aneurysms by use of Guglielmi detachable coils: prospective study applying diffusion-weighted imaging. AJNR Am J Neuroradiol 2001;22:5–10

    Abstract/FREE Full Text
25. 25.↵
    1. Soeda A,
    2. Sakai N,
    3. Sakai H,
    4. et al

    . Thromboembolic events associated with Guglielmi detachable coil embolization of asymptomatic cerebral aneurysms: evaluation of 66 consecutive cases with use of diffusion-weighted MR imaging. AJNR Am J Neuroradiol 2003;24:127–32

    Abstract/FREE Full Text
26. 26.↵
    1. Nishikawa Y,
    2. Satow T,
    3. Takagi T,
    4. et al

    . Efficacy and safety of single versus dual antiplatelet therapy for coiling of unruptured aneurysms. J Stroke Cerebrovasc Dis 2013;22:650–55

    CrossRefPubMed
27. 27.↵
    1. Lim Fat MJ,
    2. Al-Hazzaa M,
    3. Bussiere M,
    4. et al

    . Heparin dosing is associated with diffusion weighted imaging lesion load following aneurysm coiling. J Neurointerv Surg 2013;5:366–70

    Abstract/FREE Full Text
28. 28.↵
    1. Markus HS,
    2. Droste DW,
    3. Kaps M,
    4. et al

    . Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using Doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial. Circulation 2005;111:2233–40

    Abstract/FREE Full Text
29. 29.↵
    1. Mazighi M,
    2. Saint Maurice JP,
    3. Bresson D,
    4. et al

    . Platelet aggregation in intracranial stents may mimic in-stent restenosis. AJNR Am J Neuroradiol 2010;31:496–97

    Abstract/FREE Full Text
30. 30.↵
    1. Mega JL,
    2. Close SL,
    3. Wiviott SD,
    4. et al

    . Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet 2010;376:1312–19

    CrossRefPubMedWeb of Science
31. 31.↵
    1. Kim BJ,
    2. Lee SW,
    3. Park SW,
    4. et al

    . Insufficient platelet inhibition is related to silent embolic cerebral infarctions after coronary angiography. Stroke 2012;43:727–32

    Abstract/FREE Full Text
32. 32.↵
    1. Gilard M,
    2. Arnaud B,
    3. Cornily JC,
    4. et al

    . Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008;51:256–60

    CrossRefPubMed
33. 33.↵
    1. Bhatt DL,
    2. Cryer BL,
    3. Contant CF,
    4. et al

    . Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010;363:1909–17

    CrossRefPubMedWeb of Science
34. 34.↵
    1. Drazin D,
    2. Choulakian A,
    3. Nuño M,
    4. et al

    . Body weight: a risk factor for subtherapeutic antithrombotic therapy in neurovascular stenting. J Neurointerv Surg 2011;3:177–81

    Abstract/FREE Full Text
35. 35.↵
    1. Siller-Matula JM,
    2. Huber K,
    3. Christ G,
    4. et al

    . Impact of clopidogrel loading dose on clinical outcome in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. Heart 2011;97:98–105

    Abstract/FREE Full Text
36. 36.↵
    1. Price MJ,
    2. Berger PB,
    3. Teirstein PS,
    4. et al

    . Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 2011;305:1097–105

    CrossRefPubMedWeb of Science
37. 37.↵
    1. Alexopoulos D,
    2. Dimitropoulos G,
    3. Davlouros P,
    4. et al

    . Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel: the importance of CYP2C19*2 genotyping. JACC Cardiovasc Interv 2011;4:403–10

    CrossRefPubMedWeb of Science
38. 38.↵
    1. Chow M,
    2. McDougall C,
    3. O'Kelly C,
    4. et al

    . Delayed spontaneous rupture of a posterior inferior cerebellar artery aneurysm following treatment with flow diversion: a clinicopathologic study. AJNR Am J Neuroradiol 2012;33:E46–51

    Abstract/FREE Full Text
39. 39.↵
    1. Cebral JR,
    2. Mut F,
    3. Raschi M,
    4. et al

    . Aneurysm rupture following treatment with flow-diverting stents: computational hemodynamics analysis of treatment. AJNR Am J Neuroradiol 2011;32:27–33

    Abstract/FREE Full Text
40. 40.↵
    1. Kulcsár Z,
    2. Houdart E,
    3. Bonafe A,
    4. et al

    . Intra-aneurysmal thrombosis as a possible cause of delayed aneurysm rupture after flow-diversion treatment. AJNR Am J Neuroradiol 2011;32:20–25

    Abstract/FREE Full Text